Microbot CFO granted 105,000 stock options
Vaknin Rachel reported acquisition or exercise transactions in this Form 4 filing.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Vaknin Rachel reported acquisition or exercise transactions in this Form 4 filing.
Microbot Medical Inc. reported that its Chief Financial Officer, Rachel Vaknin, received a grant of stock options covering 105,000 shares of common stock. The award is a right to buy shares under the company’s 2020 Omnibus Performance Award Plan, as amended.
According to the grant terms, 25% of the options will vest and become exercisable on August 18, 2026. The remaining 75% will vest and become exercisable in equal installments on a quarterly basis over the following 30 months, subject to possible acceleration or forfeiture under the plan.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (Right to Buy) | 105,000 | $0.00 | $0.00 |
Footnotes (1)
- F1. The options vest as follows and in accordance with the terms of the Issuer's 2020 Omnibus Performance Award Plan, as amended (the "Plan"): (a) on August 18, 2026, the option shall vest and shall become exercisable with respect to 25% of the common stock; and (b) on a quarterly basis over the next 30 months, the option shall equally vest and become exercisable with respect to the remaining 75% of the common stock, subject to acceleration or forfeiture pursuant to the terms of the Plan.
AI-generated analysis. How Rhea-AI works. Not financial advice.